Myeloperoxidase, (MPO) is the most abundant metalloproteinase and is an enzyme produced by polymorphonuclear neutrophils and macrophages. It catalyzes the

conversion of chloride and hydrogen peroxide to hypochlorite and is involved in the oxidation of lipids contained within LDL particles. It generates an array of reactive oxidants and radical species that contribute to the development of atheroma and subsequent plaque rupture.It serves as a marker of plaque instability, with increased levels indicating the activation of inflammatory cells around a vulnerable plaque.

MPO has demonstrated some value as a prognostic biomarker in predicting future adverse events. Although MPO can help assess the risk of CAD in healthy individuals, the relationship between MPO and CAD is stronger in patients with established or suspected ACS.

Thank you for your contribution to my question.